630 related articles for article (PubMed ID: 25200249)
1. The IL-2 cytokine family in cancer immunotherapy.
Sim GC; Radvanyi L
Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
[TBL] [Abstract][Full Text] [Related]
2. Prospect of IL-2, IL-7, IL-15 and IL-21 for HIV immune-based therapy.
Diallo M; Zheng Y; Chen X; He Y; Zhou H; Chen Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1037-45. PubMed ID: 22169717
[TBL] [Abstract][Full Text] [Related]
3. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 signaling: functions in cancer and autoimmunity.
Davis ID; Skak K; Smyth MJ; Kristjansen PE; Miller DM; Sivakumar PV
Clin Cancer Res; 2007 Dec; 13(23):6926-32. PubMed ID: 18056166
[TBL] [Abstract][Full Text] [Related]
5. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
Liu S; Riley J; Rosenberg S; Parkhurst M
J Immunother; 2006; 29(3):284-93. PubMed ID: 16699371
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer.
Ramesh R; Ioannides CG; Roth JA; Chada S
Methods Mol Biol; 2010; 651():241-70. PubMed ID: 20686970
[TBL] [Abstract][Full Text] [Related]
7. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P; Brivio F; Viviani S; Fumagalli L
J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
[TBL] [Abstract][Full Text] [Related]
8. IL-21: roles in immunopathology and cancer therapy.
Søndergaard H; Skak K
Tissue Antigens; 2009 Dec; 74(6):467-79. PubMed ID: 19845910
[TBL] [Abstract][Full Text] [Related]
9. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.
Waldmann TA; Tagaya Y
Annu Rev Immunol; 1999; 17():19-49. PubMed ID: 10358752
[TBL] [Abstract][Full Text] [Related]
10. IL-2, IL-7, and IL-15: Multistage regulators of CD4(+) T helper cell differentiation.
Read KA; Powell MD; McDonald PW; Oestreich KJ
Exp Hematol; 2016 Sep; 44(9):799-808. PubMed ID: 27423815
[TBL] [Abstract][Full Text] [Related]
11. Functions of γC cytokines in immune homeostasis: current and potential clinical applications.
Overwijk WW; Schluns KS
Clin Immunol; 2009 Aug; 132(2):153-65. PubMed ID: 19428306
[TBL] [Abstract][Full Text] [Related]
12. [Biology and immunotherapy advance of interleukin 2 and interleukin 15-review].
Chen GH; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1088-92. PubMed ID: 19698267
[TBL] [Abstract][Full Text] [Related]
13. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
Khawam K; Giron-Michel J; Gu Y; Perier A; Giuliani M; Caignard A; Devocelle A; Ferrini S; Fabbi M; Charpentier B; Ludwig A; Chouaib S; Azzarone B; Eid P
Cancer Res; 2009 Feb; 69(4):1561-9. PubMed ID: 19190330
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 and interleukin-15: immunotherapy for cancer.
Fehniger TA; Cooper MA; Caligiuri MA
Cytokine Growth Factor Rev; 2002 Apr; 13(2):169-83. PubMed ID: 11900992
[TBL] [Abstract][Full Text] [Related]
15. IL-15: targeting CD8+ T cells for immunotherapy.
Diab A; Cohen AD; Alpdogan O; Perales MA
Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 21 treatment in a murine model as a novel potential cytokine immunotherapy for colon cancer.
Chen C; Liu X; Ren Y
Adv Clin Exp Med; 2018 May; 27(5):583-589. PubMed ID: 29616746
[TBL] [Abstract][Full Text] [Related]
18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
20. Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2.
Locker GJ; Kofler J; Stoiser B; Wilfing A; Wenzel C; Wögerbauer M; Steger GG; Zielinski CC; Mader R; Burgmann H
Eur Cytokine Netw; 2000 Sep; 11(3):391-6. PubMed ID: 11022123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
